Browse > Article
http://dx.doi.org/10.1016/j.jgr.2018.04.004

Ameliorative effects of ginseng and ginsenosides on rheumatic diseases  

Yi, Young-Su (Department of Pharmaceutical Engineering, Cheongju University)
Publication Information
Journal of Ginseng Research / v.43, no.3, 2019 , pp. 335-341 More about this Journal
Abstract
Background: Inflammation is a host-defensive innate immune response to protect the body from pathogenic agents and danger signals induced by cellular changes. Although inflammation is a host-defense mechanism, chronic inflammation is considered a major risk factor for the development of a variety of inflammatory autoimmune diseases, such as rheumatic diseases. Rheumatic diseases are systemic inflammatory and degenerative diseases that primarily affect connective tissues and are characterized by severe chronic inflammation and degeneration of connective tissues. Ginseng and its bioactive ingredients, genocides, have been demonstrated to have antiinflammatory activity and pharmacological effects on various rheumatic diseases by inhibiting the expression and production of inflammatory mediators. Methods: Literature in this review was searched in a PubMed site of National Center for Biotechnology Information. Results: The studies reporting the preventive and therapeutic effects of ginseng and ginsenosides on the pathogenesis of rheumatic diseases were discussed and summarized. Conclusion: Ginseng and ginsenosides play an ameliorative role on rheumatic diseases, and this review provides new insights into ginseng and ginsenosides as promising agents to prevent and treat rheumatic diseases.
Keywords
Ginseng; Ginsenosides; Inflammation; Macrophages; Rheumatic diseases;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Prasadam I, Akuien A, Friis TE, Fang W, Mao X, Crawford RW, Xiao Y. Mixed cell therapy of bone marrow-derived mesenchymal stem cells and articular cartilage chondrocytes ameliorates osteoarthritis development. Lab Invest 2018;98:106-16.   DOI
2 McIntyre JA, Jones IA, Han B, Vangsness Jr CT. Intra-articular mesenchymal stem cell therapy for the human joint: a systematic review. Am J Sports Med 2017. 363546517735844.
3 Deng MW, Wei SJ, Yew TL, Lee PH, Yang TY, Chu HY, Hung SC. Cell therapy with g-CSF-mobilized stem cells in a rat osteoarthritis model. Cell Transplant 2015;24:1085-96.   DOI
4 Karlsson C, Brantsing C, Egell S, Lindahl A. Notch1, Jagged1, and HES5 are abundantly expressed in osteoarthritis. Cells Tissues Organs 2008;188:287-98.   DOI
5 Wang W, Zeng L, Wang ZM, Zhang S, Rong XF, Li RH. Ginsenoside Rb1 inhibits matrix metalloproteinase 13 through down-regulating Notch signaling pathway in osteoarthritis. Exp Biol Med (Maywood) 2015;240:1614-21.   DOI
6 Zhang P. GinsenosideRg5 treatment inhibits apoptosis of chondrocytes and degradation of cartilage matrix in a rat model of osteoarthritis. Oncol Rep 2017;37:1497-502.   DOI
7 Cheng W, Jing J, Wang Z, Wu D, Huang Y. Chondroprotective effects of ginsenoside Rg1 in human osteoarthritis chondrocytes and a rat model of anterior cruciate ligament transection. Nutrients 2017;9.
8 Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526-33.   DOI
9 Yi YS. Functional role of milk fat globule-epidermal growth factor VIII in macrophage-mediated inflammatory responses and inflammatory/autoimmune diseases. Mediators Inflamm 2016;2016:5628486.
10 Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. Ann Rheum Dis 2016;75:136-41.   DOI
11 Attele AS, Wu JA, Yuan CS. Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 1999;58:1685-93.   DOI
12 Janeway Jr CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002;20:197-216.   DOI
13 Osada-Oka M, Hirai S, Izumi Y, Misumi K, Samukawa K, Tomita S, Miura K, Minamiyama Y, Iwao H. Red ginseng extracts attenuate skin inflammation in atopic dermatitis through p70 ribosomal protein S6 kinase activation. J Pharmacol Sci 2018;136:9-15.   DOI
14 Wang CZ, Anderson S, Du W, He TC, Yuan CS. Red ginseng and cancer treatment. Chin J Nat Med 2016;14:7-16.   DOI
15 Dai D, Zhang CF, Williams S, Yuan CS, Wang CZ. Ginseng on cancer: potential role in modulating inflammation-mediated angiogenesis. Am J Chin Med 2017;45:13-22.   DOI
16 Gillis CN. Panax ginseng pharmacology: a nitric oxide link? Biochem Pharmacol 1997;54:1-8.   DOI
17 Yildirim-Toruner C, Diamond B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol 2011;127:303-12. quiz 313-314.   DOI
18 Kang S, Siddiqi MH, Yoon SJ, Ahn S, Noh HY, Kumar NS, Kim YJ, Yang DC. Therapeutic potential of compound K as an IKK inhibitor with implications for osteoarthritis prevention: an in silico and in vitro study. In Vitro Cell Dev Biol Anim 2016;52:895-905.   DOI
19 So MW, Lee EJ, Lee HS, Koo BS, Kim YG, Lee CK, Yoo B. Protective effects of ginsenoside Rg3 on human osteoarthritic chondrocytes. Mod Rheumatol 2013;23:104-11.   DOI
20 Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford) 2017;56:1945-61.   DOI
21 Yang HT, Zhang JR. Treatment of systemic lupus erythematosus with saponin of ginseng fruit (SPGF): an immunological study. Zhong Xi Yi Jie He Za Zhi 1986;6. 157-159, 131-2.
22 You YL, Ling CQ, Feng YL. Efficacy of combined therapy with ginsenosides and prednisone in treating systemic lupus erythematosusea randomized, controlled and double-blinded trial. Zhongguo Zhong Xi Yi Jie He Za Zhi 2009;29:776-9.
23 You YL, Feng YL, Cai Q, Guan JL, Zhang LL, Xu MJ, Xu X, Ling CQ. Efficacy of ginsenosides combined with prednisone in patients with systemic lupus erythematosus: a prospective, randomized, double-blind, placebo-controlled trial. Zhong Xi Yi Jie He Xue Bao 2010;8:762-6.
24 Chong SK, Oberholzer VG. Ginsengeis there a use in clinical medicine? Postgrad Med J 1988;64:841-6.   DOI
25 Hasegawa H. Proof of the mysterious efficacy of ginseng: basic and clinical trials: metabolic activation of ginsenoside: deglycosylation by intestinal bacteria and esterification with fatty acid. J Pharmacol Sci 2004;95:153-7.   DOI
26 Yi YS. Folate receptor-targeted diagnostics and therapeutics for inflammatory diseases. Immune Netw 2016;16:337-43.   DOI
27 Yi YS. Caspase-11 non-canonical inflammasome: a critical sensor of intracellular lipopolysaccharide in macrophage-mediated inflammatory responses. Immunology 2017;152:207-17.   DOI
28 Yi YS. Role of inflammasomes in inflammatory autoimmune rheumatic diseases. Korean J Physiol Pharmacol 2018;22:1-15.   DOI
29 Kim JH, Yi YS, Kim MY, Cho JY. Role of ginsenosides, the main active components of Panax ginseng, in inflammatory responses and diseases. J Ginseng Res 2017;41:435-43.   DOI
30 Yun TK. Brief introduction of Panax ginseng C.A. Meyer. J Korean Med Sci. 2001;16(Suppl):S3-5.   DOI
31 Deng J, Liu Y, Duan Z, Zhu C, Hui J, Mi Y, Ma P, Ma X, Fan D, Yang H. Protopanaxadiol and protopanaxatriol-type saponins ameliorate glucose and lipid metabolism in type 2 diabetes mellitus in high-fat diet/streptozocin-induced mice. Front Pharmacol 2017;8:506.   DOI
32 Jiang S, Ren D, Li J, Yuan G, Li H, Xu G, Han X, Du P, An L. Effects of compound K on hyperglycemia and insulin resistance in rats with type 2 diabetes mellitus. Fitoterapia 2014;95:58-64.   DOI
33 Yuan HD, Kim JT, Kim SH, Chung SH. Ginseng and diabetes: the evidences from in vitro, animal and human studies. J Ginseng Res 2012;36:27-39.   DOI
34 Liu CX, Xiao PG. Recent advances on ginseng research in China. J Ethnopharmacol 1992;36:27-38.   DOI
35 Sun Y, Liu Y, Chen K. Roles and mechanisms of ginsenoside in cardiovascular diseases: progress and perspectives. Sci China Life Sci 2016;59:292-8.   DOI
36 Lee CH, Kim JH. A review on the medicinal potentials of ginseng and ginsenosides on cardiovascular diseases. J Ginseng Res 2014;38:161-6.   DOI
37 Zhang L, Virgous C, Si H. Ginseng and obesity: observations and understanding in cultured cells, animals and humans. J Nutr Biochem 2017;44:1-10.   DOI
38 Sabouri-Rad S, Sahebkar A, Tayarani-Najaran Z. Ginseng in dermatology: a review. Curr Pharm Des 2017;23:1649-66.   DOI
39 Sodrul IMD, Wang C, Chen X, Du J, Sun H. Role of ginsenosides in reactive oxygen species-mediated anticancer therapy. Oncotarget 2018;9:2931-50.   DOI
40 Chen XJ, Zhang XJ, Shui YM, Wan JB, Gao JL. Anticancer activities of protopanaxadiol-and protopanaxatriol-type ginsenosides and their metabolites. Evid Based Complement Alternat Med 2016;2016:5738694.
41 Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, McInnes IB, Solomon DH, Strand V, et al. Rheumatoid arthritis. Nat Rev Dis Primers 2018;4:18001.   DOI
42 Kim HA, Kim S, Chang SH, Hwang HJ, Choi YN. Anti-arthritic effect of ginsenoside Rb1 on collagen induced arthritis in mice. Int Immunopharmacol 2007;7:1286-91.   DOI
43 Zhao S, Zheng MX, Chen HE, Wu CY, Wang WT. Effect of panax notoginseng saponins injection on the p38MAPK pathway in lung tissue in a rat model of hypoxic pulmonary hypertension. Chin J Integr Med 2015;21:147-51.   DOI
44 Lee HW, Lim HJ, Jun JH, Choi J, Lee MS. Ginseng for treating hypertension: a systematic review and meta-analysis of double blind, randomized, placebocontrolled trials. Curr Vasc Pharmacol 2017;15:549-56.
45 Yi YS, Ayala-Lopez W, Kularatne SA, Low PS. Folate-targeted hapten immunotherapy of adjuvant-induced arthritis: comparison of hapten potencies. Mol Pharm 2009;6:1228-36.   DOI
46 Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum 2010;62:1576-82.   DOI
47 Tobon GJ, Youinou P, Saraux A. The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. J Autoimmun 2010;35:10-4.   DOI
48 Szekanecz Z, Koch AE. Macrophages and their products in rheumatoid arthritis. Curr Opin Rheumatol 2007;19:289-95.   DOI
49 Choi YS, Kang EH, Lee EY, Gong HS, Kang HS, Shin K, Lee EB, Song YW, Lee YJ. Joint-protective effects of compound K, a major ginsenoside metabolite, in rheumatoid arthritis: in vitro evidence. Rheumatol Int 2013;33:1981-90.   DOI
50 Chang SH, Choi Y, Park JA, Jung DS, Shin J, Yang JH, Ko SY, Kim SW, Kim JK. Anti-inflammatory effects of BT-201, an n-butanol extract of Panax notoginseng, observed in vitro and in a collagen-induced arthritis model. Clin Nutr 2007;26:785-91.   DOI
51 Zhang JH, Wang JP, Wang HJ. Clinical study on effect of total panax notoginseng saponins on immune related inner environment imbalance in rheumatoid arthritis patients. Zhongguo Zhong Xi Yi Jie He Za Zhi 2007;27:589-92.
52 Heidari B. Knee osteoarthritis prevalence, risk factors, pathogenesis and features: Part I. Caspian J Intern Med 2011;2:205-12.
53 Zhang Y, Jordan JM. Epidemiology of osteoarthritis. Clin Geriatr Med 2010;26:355-69.   DOI
54 Ahn EJ, Choi GJ, Kang H, Baek CW, Jung YH, Woo YC, Bang SR. Antinociceptive effects of ginsenoside Rg3 in a rat model of incisional pain. Eur Surg Res 2016;57:211-23.   DOI
55 Yu T, Rhee MH, Lee J, Kim SH, Yang Y, Kim HG, Kim Y, Kim C, Kwak YS, Kim JH, et al. Ginsenoside Rc from Korean red ginseng (panax ginseng C.A. Meyer) attenuates inflammatory symptoms of gastritis, hepatitis and arthritis. Am J Chin Med 2016;44:595-615.   DOI
56 Lee S, Youn K, Jeong WS, Ho CT, Jun M. Protective effects of red ginseng oil against abeta25-35-induced neuronal apoptosis and inflammation in PC12 cells. Int J Mol Sci 2017;18.
57 Ong WY, Farooqui T, Koh HL, Farooqui AA, Ling EA. Protective effects of ginseng on neurological disorders. Front Aging Neurosci 2015;7:129.
58 Kim WJ, Kang H, Choi GJ, Shin HY, Baek CW, Jung YH, Woo YC, Kim JY, Yon JH. Antihyperalgesic effects of ginseng total saponins in a rat model of incisional pain. J Surg Res 2014;187:169-75.   DOI
59 Evans CH, Ghivizzani SC, Robbins PD. Gene delivery to joints by intra-articular injection. Hum Gene Ther 2018;29:2-14.   DOI
60 Brandt KD, Dieppe P, Radin E. Etiopathogenesis of osteoarthritis. Med Clin North Am. 2009;93:1-24. xv.   DOI
61 Madry H, Cucchiarini M. Gene therapy for human osteoarthritis: principles and clinical translation. Expert Opin Biol Ther 2016;16:331-46.   DOI
62 Zhang DW, Yang QS, Zhu JY, Cao XR, Li LW, Zhu QS. Amelioration of osteoarthritis by intra-articular hyaluronan synthase 2 gene therapy. Med Hypotheses 2007;69:1111-3.   DOI
63 Mason JB, Gurda BL, Hankenson KD, Harper LR, Carlson CS, Wilson JM, Richardson DW. Wnt10b and Dkk-1 gene therapy differentially influenced trabecular bone architecture, soft tissue integrity, and osteophytosis in a skeletally mature rat model of osteoarthritis. Connect Tissue Res. 2017;58:542-52.   DOI
64 Noh MJ, Lee KH. Orthopedic cellular therapy: an overview with focus on clinical trials. World J Orthop 2015;6:754-61.   DOI